First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome

Press/Media

Period	6 May 2020

Media coverage

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	Wallstreet Online
Country/Territory	Germany
Date	6/05/20
URL	https://www.wallstreet-online.de/nachricht/12489534-first-patients-dosed-phase-2-3-randomized-controlled-trial-of-mesoblast-s-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns